Literature DB >> 7435450

Laboratory monitoring of heparin therapy--the effect of different salts of heparin on the activated partial thromboplastin time.

E I Banez, D A Triplett, J Koepke.   

Abstract

Data from the 1978 CAP Hematology Survey were analyzed for the effect of sodium and calcium salts of heparin on the activated partial thromboplastin time (APTT). The results indicate that the sodium salt of heparin prolongs the APTT more than the calcium salt at a heparin concentration of 0.2 units/ml. Furthermore, there was a variable response of the different APTT reagents to the different heparin salts. Data from the 1979 CAP Hematology Survey showed a greater sensitivity of the Automated APTT reagent and the Platelin Plus Activator of General Diagnostics compared with Actin (Dade) and Thrombofax (Ortho) at therapeutic heparin levels of 0.2 units/ml to 0.4 units/ml. The 1979 CAP heparin questionnaire results are presented and analyzed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7435450

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

1.  Activated clotting time or activated partial thromboplastin time as the method of choice for patients undergoing neuroradiological intervention.

Authors:  R Kubalek; A Berlis; M Schwab; J Klisch; M Schumacher
Journal:  Neuroradiology       Date:  2003-03-28       Impact factor: 2.804

2.  Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage.

Authors:  S Kitchen; I Jennings; T A Woods; F E Preston
Journal:  J Clin Pathol       Date:  1996-01       Impact factor: 3.411

3.  The use of the activated clotting time for monitoring heparin therapy in critically ill patients.

Authors:  Jan J De Waele; Sebastiaan Van Cauwenberghe; Eric Hoste; Dominique Benoit; Francis Colardyn
Journal:  Intensive Care Med       Date:  2003-01-16       Impact factor: 17.440

Review 4.  Pharmacokinetic optimisation of the treatment of embolic disorders.

Authors:  D M Lutomski; M Bottorff; K Sangha
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.